Stock fact sheet · data as of

Alpha Teknova, Inc. (TKNO): fair value, margin of safety and Wheel Score

Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative / Distressed

Close7.79
GLS fair value-no model value
Margin of safety-
Wheel Score42Weakout of 100
Health3/9Piotroski F-score
Moat1.5/10GLS 10-year score
Market cap$418M236k shares a day
Implied vol.92%near-the-money, 20-60 d
P/E-EPS -0.31
Dividend yieldnone
Beta0.73moves less than the market
Next earnings4 Nov 2026in 19 days (after the close)

Is TKNO undervalued?

Alpha Teknova, Inc. (TKNO) closed at 7.79 on 16 Oct 2026. None of the nine GLS valuation models produced a positive value for the stock - the company lost money over the last twelve months, EPS -0.31, it pays no dividend and its debts exceed what its assets would fetch - so there is no GLS average fair value and no margin of safety to report. The quality, option and event numbers below still apply; the Quote page's Wall Street View shows what analysts expect instead.

The nightly engine files TKNO under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for TKNO

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-0.0056-100%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target8.00+3%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: TKNO passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -20.6%, ROE -25.1%, ROA -16.7% - with debt at 0.22 times equity and negative free cash flow.

Alpha Teknova, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Lab Essentials 75%, Clinical Solutions 20%, Other Product 5% (quarter Q2 FY2026).

Institutional ownership scores 2/10, insider activity 10/10 and Congressional trading 1/10 on the GLS smart-money scales; the last recorded Congressional buy was on 10 Aug 2026.

Piotroski F-score3 / 9ROIC-20.6%
GLS Moat1.5 / 10ROE-25.1%
Debt / equity0.22ROA-16.7%
Free-cash-flow yield-1.7%Payout ratio0%
Institutions2 / 10Insiders · Congress10 · 1 / 10

Wheel Score 42: Weak

TKNO scores 42 out of 100 on the Wheel Score, in the Weak band (under 50). Value 13/25, Health 7/20, Moat 2/15, Premium 12/20, Stability 9/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.

Implied volatility is 92% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (12 of 20) because volatility this high usually comes with a reason. Chain open interest is thin - 489 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.

Volume runs at 236k shares a day on a market cap of $418M, with a beta of 0.73 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 9 of 20.

PartPointsFrom
Value13 / 250% margin of safety
Health7 / 20Piotroski 3/9
Moat2 / 15moat 1.5/10
Premium12 / 20implied volatility 92%
Stability9 / 20236k shares/day, $418M cap, beta 0.73

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 4 Nov 2026 (after the close), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Drug Manufacturers - Specialty & Generic

The 12 companies below are the closest to Alpha Teknova, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
NIKA
Nika Pharmaceuticals Inc.
0.41000.0000-22736543%15No options$430M
KMDA
Kamada Ltd.
7.8314.12+45%67Good$452M
VRNO
Verano Holdings Corp
5.1441.44+88%39No options$376M
EBS
Emergent BioSolutions Inc.
7.1824.93+71%45Weak$368M
TLRY
Tilray Brands, Inc.
3.14--45Weak$351M
EOLS
Evolus, Inc.
7.578.80+14%45Weak$500M
EVO
Evotec SE
1.42--29No options$504M
AQST
Aquestive Therapeutics, Inc.
4.06--45Weak$510M
GLAS
Glass House Brands Inc
3.7154.67+93%45Weak$326M
CGC
Canopy Growth Corporation
0.7355--37Weak$311M
IRWD
Ironwood Pharmaceuticals, Inc.
3.7712.28+69%69Good$623M
ELTP
Elite Pharmaceuticals, Inc.
0.25006.20+96%39No options$269M

⚖ Compare TKNO with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about TKNO

Is TKNO undervalued right now?

The GLS models could not value TKNO (the company lost money over the last twelve months, EPS -0.31, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 7.79 against.

What is the Wheel Score of TKNO and what does it mean?

TKNO scores 42 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for TKNO?

None of the nine GLS models produced a positive value for TKNO (the company lost money over the last twelve months, EPS -0.31, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.

When does Alpha Teknova, Inc. report earnings next?

The next earnings report is due on 4 Nov 2026 (after the close), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does TKNO have listed options, and how liquid are they?

Yes. The nightly snapshot found 58 listed contracts with 489 open interest across all expiries and implied volatility of 92% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.